Patent application number | Description | Published |
20090018054 | Cholesteryl Ester Transfer Protein Inhibitors - Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A | 01-15-2009 |
20090042892 | Cetp Inhibitors - Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B. | 02-12-2009 |
20090075979 | CETP Inhibitors - Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R | 03-19-2009 |
20090137548 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B. | 05-28-2009 |
20090264405 | Cetp Inhibitors - Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. | 10-22-2009 |
20090306202 | D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands - The present invention is directed to D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included. | 12-10-2009 |
20100029678 | DIURETICS - A compound having the structure | 02-04-2010 |
20100099716 | CETP INHIBITORS - Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: | 04-22-2010 |
20100144810 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 06-10-2010 |
20100152258 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure (Formula I), wherein Y is —Y | 06-17-2010 |
20100152259 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure (Formula I), wherein R an angiotensin receptor antagonist active group, Y is Y | 06-17-2010 |
20100167986 | Cholesteryl Ester Transfer Protein Inhibitors - Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A | 07-01-2010 |
20100249024 | CETP INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A | 09-30-2010 |
20100273845 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 10-28-2010 |
20100292192 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 11-18-2010 |
20100298277 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 11-25-2010 |
20110065765 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 03-17-2011 |
20110178059 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B. | 07-21-2011 |
20110201621 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 08-18-2011 |
20110218177 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS - The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient. | 09-08-2011 |
20110230532 | NITROOXY CYCLOALKANE DERIVATIVES - A compound having the structure wherein Y is selected from the group consisting of —C(O)OR | 09-22-2011 |
20120202845 | DIURETICS - A compound having the structure formula (I) or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 08-09-2012 |
20120208838 | DIURETICS - A compound having the structure (I) wherein R is selected from the group consisting of 1) and 2), or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 08-16-2012 |
20120232039 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure | 09-13-2012 |
20120238608 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) —C(R1R2) (C(R3R4))0-1Y1R5, and 3) —C(R1R2)—O—Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is; Y1 is selected from the group consisting of C(O)—O— and P(O)(OR6)—O—; and R6 is hydrogen or CH3, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 09-20-2012 |
20130053352 | DIAZENIUMDIOLATE CYCLOPENTYL DERIVATIVES - A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R | 02-28-2013 |
20130059823 | Diazeniumdiolate Cyclohexyl Derivatives - A compound having the structure (I) or a pharmaceutically acceptable salt thereof, wherein R | 03-07-2013 |
20130289003 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 10-31-2013 |
20130296278 | Diazeniumdiolate Derivatives - A compound having the structure (I) useful for treating hypertension, pulmonary arterial hypertension, congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 11-07-2013 |
20140045819 | ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. | 02-13-2014 |
20140088048 | DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES - A compound having the structure | 03-27-2014 |
20140221383 | CETP INHIBITORS - Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: | 08-07-2014 |
20140235667 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to imidazopyridyl compounds of the structural formula: I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase. | 08-21-2014 |
20140249130 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS - The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer. | 09-04-2014 |